Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiviral drug antineoplastic agent |
| gptkbp:approvedBy |
gptkb:India
gptkb:Mexico gptkb:United_States |
| gptkbp:ATCCode |
gptkb:P01AX11
|
| gptkbp:bioavailability |
unknown
|
| gptkbp:brand |
Alinia
Daxon Kidonax Nitazox |
| gptkbp:CASNumber |
55981-09-4
|
| gptkbp:category |
antiviral
antiparasitic nitro compound antiprotozoal thiazole |
| gptkbp:chemicalFormula |
C12H9N3O5S
|
| gptkbp:contraindication |
severe renal impairment
severe hepatic impairment hypersensitivity to nitazoxanide |
| gptkbp:developedBy |
Romark Laboratories
|
| gptkbp:discoveredBy |
Jean-François Rossignol
|
| gptkbp:eliminationHalfLife |
1.1 hours (tizoxanide)
|
| gptkbp:excretion |
urine
bile feces |
| gptkbp:firstDescribed |
1984
|
| https://www.w3.org/2000/01/rdf-schema#label |
nitazoxanide
|
| gptkbp:IUPACName |
2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits pyruvate:ferredoxin oxidoreductase enzyme-dependent electron transfer
|
| gptkbp:metabolism |
tizoxanide
|
| gptkbp:molecularWeight |
307.28 g/mol
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinBinding |
>99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain headache |
| gptkbp:usedFor |
treatment of giardiasis
treatment of amoebiasis treatment of cryptosporidiosis treatment of viral gastroenteritis |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Giardiasis
|
| gptkbp:bfsLayer |
5
|